Unichem Laboratories share price today

Unichem Laboratories Ltd's share price was ₹505.45 at the close on 4 November 2026. It has been rising for 16 weeks. That is 4.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹284 and ₹639, and at that close it sat 62% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Unichem Laboratories Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row.

Over the last 11 years the share price moved +154% while the NIFTY 500 moved +257%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

7 points on a year earlier.

1. Indian funds and insurers (DIIs) cut their stake for 8 quarters in a row

   From 11.7% to 9.4% of the company by the September 2026 quarter.

2. Revenue grew again in the June 2026 quarter

   Revenue was ₹633 crore, +20.1% on a year earlier (₹527 crore), after 2 quarters of decline.

3. Operating margin up 6.7 points on a year earlier

   11% in the June 2026 quarter, from 4.3%.

For April to June 2026 (the quarter ended 30 June 2026), Unichem Laboratories reported revenue of ₹633 crore, up 20.1% from ₹527 crore a year earlier, and a profit of ₹41.0 crore, against a loss of ₹10.0 crore a year earlier.

Unichem Laboratories results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Unichem Laboratories closed at ₹505.45 on 4 November 2026, up 9.9% from ₹460.10 a year earlier (7 November 2025) and up 126.5% over five years. Its highest weekly close since February 2016 was ₹899.65 on 8 November 2024.

Unichem Laboratories share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

564 weekly closes from 26 February 2016 to 4 November 2026.

4 Nov 2026: Unichem Laboratories closed at ₹505.45, up 4.5% on the week and down 5.5% on the month. Results for April to June 2026: Revenue up 20.1% on a year earlier.

Unichem Laboratories paid no dividend in the 12 months to 5 November 2026. The last was a dividend of ₹4 a share, ex-date 1 August 2022.

Unichem Laboratories dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Not in its latest year. Unichem Laboratories Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 7 of its last 13 reported years, so there is a history but no current dividend.

From the NSE corporate-actions record, read 5 November 2026.

Unichem Laboratories is on one of our India lists: Pharma stocks.

Unichem Laboratories Ltd earned ₹41.0 Cr of net profit in the Jun 2026 quarter. Full-year FY26 profit was ₹253 Cr. Over 10 years profit has grown 8.9% a year on average. That is 6.5% of the quarter's revenue. The same quarter a year earlier lost ₹10.0 Cr. 4 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹253 Cr (+83.3% on the year before).

On average over the last four quarters, profit changed +42.7% and revenue +7.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Unichem Laboratories Ltd reported ₹633 Cr of revenue in the Jun 2026 quarter, +20.1% on the same quarter a year earlier. Over 10 years it has grown 5.1% a year on average. The last full year, FY26, came in at ₹2,202 Cr. The last four reported quarters add to ₹2,308 Cr.

Revenue is everything the company billed its customers in the period.

FY26 revenue was ₹2,202 Cr, +4.3% on the year before.

Recent pace: the last four quarters grew +7.5% on average, against 5.1% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +7.1%, against +13.3% a year over the last 8 quarters (rolling over).

Unichem Laboratories Ltd's operating margin was 11.0% in the Jun 2026 quarter, 6.7 percentage points higher than the same quarter a year ago. Across 13 years it has been between −16.0% and 16.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +6.8 percentage points on the year while gross margin changed +0.9 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years Unichem Laboratories Ltd's operations used more cash than they brought in, so cash conversion was −62%, a gap worth watching. In FY26 it brought in ₹4.0 Cr of operating cash against ₹253 Cr of profit. After ₹107 Cr of spending on assets, free cash was −₹103 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why −62% of profit came in as cash: the cash cycle got 32 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Unichem Laboratories Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 358 days in FY26, down from 390 days in FY21. It spent ₹282 Cr on assets over the last 3 years. Customers take 137 days to pay, and stock sits for 349 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹2,202 Cr, each day of that cycle ties up about ₹6.0 Cr, so roughly ₹2,160 Cr is tied up in the business at any time.

FY26: customers took 137 days to pay and stock sat for 349 days, about 11.5 months of sales sitting as stock, for a full cycle of 358 days, shorter than FY21's 390.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 349 days. Customers pay about 137 days after that. Suppliers are paid at 128 days. Together that makes the 358-day cycle.

Spending on assets: ₹282 Cr over the last 3 years, against ₹373 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹100 Cr (FY26): assets paid for that are not earning yet.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

Unichem Laboratories Ltd's P/E is 29.1×, in the middle of its own history: higher than 57% of past readings. Its usual P/E (the middle reading) is 26.6×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.